- J&J sees Spravato sales surge as psychedelic competitors loomPsychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.BioSpace · 11d ago↗ source
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsPrediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.STAT · 11d ago↗ source
- STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckleyEli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.